Combination of Statin and Ezetimibe versus Statin Monotherapy on Cardiovascular Disease and Type 2 Diabetes Incidence among Adults with Impaired Fasting Glucose: a Propensity- Matched Nationwide Cohort Study

키워드

참고문헌 (30)

1. Ridker PM, "Cardiovascular benefits and diabetes risks of statin therapy in primary prevention : an analysis from the JUPITER trial", Lancet, 380, pp.565~571 (2012)
2. Rajpathak SN, "Intensive statin therapy, compared with moderate dose, increases risk of new onset diabetes but decreases risk of cardiovascular events", Evid Based Med, 17, pp.55~56 (2012)
3. Sattar N, "Statins and risk of incident diabetes : a collaborative meta-analysis of randomised statin trials", Lancet, 375, pp.735~742 (2010)
4. Zafrir B, "Lipid-lowering therapies, glucose control and incident diabetes : evidence, mechanisms and clinical implications", Cardiovasc Drugs Ther, 28, pp.361~377 (2014)
5. Barkas F, "Statin therapy with or without ezetimibe and the progression to diabetes", J Clin Lipidol, 10, pp.306~313 (2016)
6. 정찬희, "Diabetes Fact Sheets in Korea, 2020: An Appraisal of Current Status", Diabetes and Metabolism Journal, 45(1), pp.1~10 (2021), 대한당뇨병학회[DOI]
7. Seong SC, "Data resource profile : the National Health Information Database of the National Health Insurance Service in South Korea", Int J Epidemiol, 46, pp.799~800 (2017)
8. Lee YB, "Risk of early mortality and cardiovascular disease in type 1 diabetes : a comparison with type 2 diabetes, a nationwide study", Cardiovasc Diabetol, 18, pp.157~ (2019)
9. 이용호, "Data Analytic Process of a Nationwide Population-Based Study Using National Health Information Database Established by National Health Insurance Service", Diabetes and Metabolism Journal, 40(1), pp.79~82 (2016), 대한당뇨병학회[DOI]
10. Lee YB, "Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status : a nationwide population-based study", Cardiovasc Diabetol, 19, pp.77~ (2020)
11. Lee YB, "Risk of end-stage renal disease from chronic kidney disease defined by decreased glomerular filtration rate in type 1 diabetes: a comparison with type 2diabetes and the effect of metabolic syndrome", Diabetes Metab Res Rev, 35, pp.e3197~ (2019)
12. Lee YB, "Risk of type 2 diabetes according to the cumulative exposure to metabolic syndrome or obesity : a nationwide population-based study", J Diabetes Investig, 11, pp.1583~1593 (2020)
13. Lee YB, "Variability in estimated glomerular filtration rate and the incidence of type 2 diabetes : a nationwide population-based study", BMJ Open Diabetes Res Care, 8, pp.e001187~ (2020)
14. Noh J, "Trends in the pervasiveness of type 2 diabetes, impaired fasting glucose and co-morbidities during an 8-year-follow-up of nationwide Korean population", Sci Rep, 7, pp.46656~ (2017)
15. Kim MK, "Cholesterol variability and the risk of mortality, myocardial infarction, and stroke : a nationwide population-based study", Eur Heart J, 38, pp.3560~3566 (2017)
16. Kim MK, "Blood pressure and development of cardiovascular disease in Koreans with type 2 diabetes mellitus", Hypertension, 73, pp.319~326 (2019)
17. Lee YB, "Gamma-glutamyl transferase variability and risk of dementia : a nationwide study", Int J Geriatr Psychiatry, 35, pp.1105~1114 (2020)
18. Stampfer MJ, "Effects of moderate alcohol consumption on cognitive function in women", N Engl J Med, 352, pp.245~253 (2005)
19. Lee YB, "Optimal blood pressure for patients with chronic kidney disease : a nationwide population-based cohort study", Sci Rep, 11, pp.1538~ (2021)
20. Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
21. Giugliano RP, "Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus : results from IMPROVE-IT(Improved Reduction of Outcomes : Vytorin Efficacy International Trial)", Circulation, 137, pp.1571~1582 (2018)
22. 홍남기, "Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis", Endocrinology and Metabolism, 33(2), pp.219~227 (2018), 대한내분비학회
23. Wu H, "Effect of ezetimibe on glycemic control : a systematic review and meta-analysis of randomized controlled trials", Endocrine, 60, pp.229~239 (2018)
24. Nakamura A, "Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabeticmetabolic syndrome patients with coronary artery disease", Heart Vessels, 34, pp.916~925 (2019)
25. Chang E, "Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK", ERK pathway rather than dipeptidyl peptidase 4 inhibition, 2015, pp.64, 633~641
26. Kim J, "Effect of statins on fasting glucose in non-diabetic individuals : nationwide population-based health examination in Korea", Cardiovasc Diabetol, 17, pp.155~ (2018)
27. Kim NH, "Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study", BMJ, 366, pp.l5125~ (2019)
28. Lee M, "Nationwide trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4inhibitors", Diabetes Care, 42, pp.2057~2064 (2019)
29. Lee JK, "How should we measure medication adherence in clinical trials and practice?", Ther Clin Risk Manag, 3, pp.685~690 (2007)
30. Choo PW, "Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy", Med Care, 37, pp.846~857 (1999)

관련 논문AI추천